FMP

FMP

Enter

AYTU - Aytu BioPharma, Inc.

Financial Summary of Aytu BioPharma, Inc.(AYTU), Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing

photo-url-https://financialmodelingprep.com/image-stock/AYTU.png

Aytu BioPharma, Inc.

AYTU

NASDAQ

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.

2.9 USD

0.1243 (4.28%)

About

ceo

Mr. Joshua R. Disbrow

sector

Healthcare

industry

Drug Manufacturers - Specialty & Generic

website

https://aytubio.com

exchange

NASDAQ

Description

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children...

CIK

0001385818

ISIN

US0547548588

CUSIP

054754874

Address

373 Inverness Parkway

Phone

720 437 6580

Country

US

Employee

150

IPO Date

Sep 25, 2008

Summary

CIK

0001385818

Exchange

NASDAQ

Industry

Drug Manufacturers -...

Sector

Healthcare

CUSIP

054754874

ISIN

US0547548588

Country

US

Price

2.9

Beta

-1.26

Volume Avg.

20.91k

Market Cap

16.17M

Shares

-

52-Week

1.38-3.5

DCF

3.96

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.72

P/B

-

Website

https://aytubio.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest AYTU News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep